To listen to the conference call dial 1-888-459-5609. International callers can dial 1-973-321-1024. When prompted, use PIN number 59249560. Dial in approximately ten minutes prior to the scheduled teleconference time. A rebroadcast of the call will be available starting approximately two hours after the conference call ends, through midnight (E.T.) Tuesday, March 27, 2012. The replay of the conference call can be accessed by dialing 1-800-585-8367 (International callers can dial 1-404-537-3406) and, when prompted, use the same PIN number 59249560.
Enzo’s conference call can also be accessed live over the Internet at http://phoenix.corporate-ir.net/phoenix.zhtml?p=irol-eventDetails&c=94391&eventID=4734348.
To listen to the live call, individuals should go to the web site at least 15 minutes early to register, download and install any necessary audio software. Any pop up blocker installed on your PC should be disabled while accessing the webcast. A replay will be available for two weeks after the original broadcast.
A press release announcing second quarter results will be distributed Monday, March 12, 2012 after the market close.
Enzo Biochem is engaged in the research, development and manufacture of innovative health care products based on molecular biology and genetic engineering techniques, and in providing diagnostic services to the medical community.
Except for historical information, the matters discussed in this news release may be considered "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include declarations regarding the intent, belief or current expectations of the Company and its management, including those related to cash flow, gross margins, revenues, and expenses are dependent on a number of factors outside of the control of the company including, inter alia, the markets for the Company’s products and services, costs of goods and services, other expenses, government regulations, litigations, and general business conditions. See Risk Factors in the Company’s Form 10-K for the fiscal year ended July 31, 2010. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that could materially affect actual results. The Company disclaims any obligations to update any forward-looking statement as a result of developments occurring after the date of this press release.
For: Enzo Biochem, Inc.
Steve Anreder, 212-532-3232 or Michael Wachs, CEOcast, Inc., 212-732-4300